LT2846780T - 1,1-dimetiletil [(1s)-1-{[(2s,4r)-4-(7-chlor-4metoksiizochinolin-1-iloksi)-2-({(1r,2s)-1-[(ciklopropilsulfonil)karbamoil]-2-etenilciklopropil}karbamoil)pirolidin-1-il]karbonil}-2,2-dimetilpropil]karbamato ištirpinamų kapsulių kompozicija - Google Patents

1,1-dimetiletil [(1s)-1-{[(2s,4r)-4-(7-chlor-4metoksiizochinolin-1-iloksi)-2-({(1r,2s)-1-[(ciklopropilsulfonil)karbamoil]-2-etenilciklopropil}karbamoil)pirolidin-1-il]karbonil}-2,2-dimetilpropil]karbamato ištirpinamų kapsulių kompozicija

Info

Publication number
LT2846780T
LT2846780T LTEP13722217.0T LT13722217T LT2846780T LT 2846780 T LT2846780 T LT 2846780T LT 13722217 T LT13722217 T LT 13722217T LT 2846780 T LT2846780 T LT 2846780T
Authority
LT
Lithuania
Prior art keywords
carbamoyl
ethenylcyclopropyl
cyclopropylsulfonyl
dimethylpropyl
dimethylethyl
Prior art date
Application number
LTEP13722217.0T
Other languages
English (en)
Lithuanian (lt)
Inventor
Robert Kevin Perrone
Original Assignee
Bristol-Myers Squibb Holdings Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2846780(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Holdings Ireland filed Critical Bristol-Myers Squibb Holdings Ireland
Publication of LT2846780T publication Critical patent/LT2846780T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP13722217.0T 2012-05-07 2013-04-30 1,1-dimetiletil [(1s)-1-{[(2s,4r)-4-(7-chlor-4metoksiizochinolin-1-iloksi)-2-({(1r,2s)-1-[(ciklopropilsulfonil)karbamoil]-2-etenilciklopropil}karbamoil)pirolidin-1-il]karbonil}-2,2-dimetilpropil]karbamato ištirpinamų kapsulių kompozicija LT2846780T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261643454P 2012-05-07 2012-05-07
PCT/US2013/038770 WO2013169520A1 (en) 2012-05-07 2013-04-30 Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate

Publications (1)

Publication Number Publication Date
LT2846780T true LT2846780T (lt) 2018-11-12

Family

ID=48428670

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13722217.0T LT2846780T (lt) 2012-05-07 2013-04-30 1,1-dimetiletil [(1s)-1-{[(2s,4r)-4-(7-chlor-4metoksiizochinolin-1-iloksi)-2-({(1r,2s)-1-[(ciklopropilsulfonil)karbamoil]-2-etenilciklopropil}karbamoil)pirolidin-1-il]karbonil}-2,2-dimetilpropil]karbamato ištirpinamų kapsulių kompozicija

Country Status (33)

Country Link
US (1) US20130302414A1 (enExample)
EP (1) EP2846780B1 (enExample)
JP (1) JP6276756B2 (enExample)
KR (1) KR20150004921A (enExample)
CN (1) CN104363899A (enExample)
AR (1) AR090954A1 (enExample)
AU (1) AU2013260005B2 (enExample)
BR (1) BR112014027676A2 (enExample)
CA (1) CA2872765A1 (enExample)
CL (1) CL2014003012A1 (enExample)
CO (1) CO7141457A2 (enExample)
CY (1) CY1120756T1 (enExample)
DK (1) DK2846780T3 (enExample)
EA (1) EA028749B1 (enExample)
ES (1) ES2688817T3 (enExample)
HR (1) HRP20181583T1 (enExample)
IL (1) IL235466B (enExample)
LT (1) LT2846780T (enExample)
MX (1) MX358545B (enExample)
MY (1) MY171378A (enExample)
NZ (1) NZ630248A (enExample)
PE (1) PE20142439A1 (enExample)
PH (1) PH12014502405A1 (enExample)
PL (1) PL2846780T3 (enExample)
PT (1) PT2846780T (enExample)
RS (1) RS57881B1 (enExample)
SG (1) SG11201406964QA (enExample)
SI (1) SI2846780T1 (enExample)
SM (1) SMT201800506T1 (enExample)
TW (1) TWI577392B (enExample)
UY (1) UY34785A (enExample)
WO (1) WO2013169520A1 (enExample)
ZA (1) ZA201408967B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013169577A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
US9499550B2 (en) 2012-10-19 2016-11-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
WO2019130341A1 (en) * 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir
PL3765024T3 (pl) 2018-03-14 2024-08-05 KaNDy Therapeutics Limited <div>Nowa formulacja farmaceutyczna zawierająca podwójnych antagonistów receptora nk-1/nk-3</div>
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
EE200300201A (et) * 2000-10-31 2003-08-15 Boehringer Ingelheim Pharmaceuticals, Inc. Püranoonsete proteaasi inhibiitorite iseemulgeeruva kompositsiooni oraalne doos
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
TWI480272B (zh) * 2008-10-09 2015-04-11 Anadys Pharmaceuticals Inc 藉由５，６－二氫－１ｈ－吡啶－２－酮與一或多種其他抗病毒化合物的組合物抑制ｃ型肝炎病毒的方法
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Also Published As

Publication number Publication date
HK1204552A1 (en) 2015-11-27
RS57881B1 (sr) 2019-01-31
MX358545B (es) 2018-08-24
TW201350145A (zh) 2013-12-16
MX2014013220A (es) 2015-05-11
CN104363899A (zh) 2015-02-18
PE20142439A1 (es) 2015-01-28
US20130302414A1 (en) 2013-11-14
WO2013169520A1 (en) 2013-11-14
PH12014502405A1 (en) 2015-01-12
EP2846780A1 (en) 2015-03-18
EA028749B1 (ru) 2017-12-29
PT2846780T (pt) 2018-10-26
AU2013260005B2 (en) 2017-07-13
SG11201406964QA (en) 2014-11-27
JP6276756B2 (ja) 2018-02-07
CL2014003012A1 (es) 2015-07-10
NZ630248A (en) 2016-11-25
EP2846780B1 (en) 2018-07-18
CY1120756T1 (el) 2019-12-11
SMT201800506T1 (it) 2018-11-09
HRP20181583T1 (hr) 2018-11-30
IL235466B (en) 2019-03-31
BR112014027676A2 (pt) 2017-06-27
ZA201408967B (en) 2016-10-26
AR090954A1 (es) 2014-12-17
AU2013260005A1 (en) 2015-01-15
KR20150004921A (ko) 2015-01-13
UY34785A (es) 2013-11-29
TWI577392B (zh) 2017-04-11
PL2846780T3 (pl) 2018-11-30
ES2688817T3 (es) 2018-11-07
MY171378A (en) 2019-10-10
CA2872765A1 (en) 2013-11-14
JP2015516418A (ja) 2015-06-11
DK2846780T3 (en) 2018-09-17
SI2846780T1 (sl) 2018-09-28
CO7141457A2 (es) 2014-12-12
EA201492039A1 (ru) 2015-02-27

Similar Documents

Publication Publication Date Title
IL235466B (en) Dissolved capsule formulation of 1,1–dimethylethyl[(71)–4–(r4,s2)]}–1–(s–chloro–4 methoxyisoquinoline–1–yloxy)–2–{(11–(s2,r– [(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidine-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
WO2014052360A3 (en) Glycoprotein preparations
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
WO2011159781A3 (en) Bitter taste modulators
MY169048A (en) Polymorph of n- (2-methoxybenzoyl) -4- [(methylaminocarbonyl) amino] benzenesulfonamide
IL235654A0 (en) A pharmaceutical preparation containing (1r, 4r) - 6&#39; - fluoro - n, n - dimethyl - 4 - phenyl - 4&#39;, 9&#39; - dihydro - 3&#39;h - spiro [cyclohexane - 1, 1&#39; - pyrano [3, 4 ,b] Indole] – 4 – amine and anticonvulsant drug
MX356245B (es) Composicion farmaceutica que comprende (1r,4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3&#39;h-espiro[ciclohexan-1,1´-pirano[3,4,b] indol]-4-amina y un gabapentinoide.
IL235657A0 (en) Pharmacy device containing (1r, 4r) - 6&#39; - fluoro - n, n - dimethyl - 4 - phenyl - 4&#39;, 9&#39; - dihydro - 3&#39;h - spiro [cyclohexane - 1, 1&#39; - pyrano [3, 4 ,b] indole] – 4 – amine and antidepressants
LT2849747T (lt) Farmacinė kompozicija, apimanti (1r,4r)-6`-fluor-n,n-dimetil-4-fenil-4`,9`-dihidro-3`h-spiro[cikloheksan-1,1`-pirano [3,4,b]indol]-4-aminą ir nsar
BR112014028569A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n , n-dimetil-4 ,9-di-hidro-3h-espiro[ciclo-hexano-1 ,1-pirano-[3,4,b]indol]-4-amina e um oxicam
TH1401006625A (th) สูตรผสมแคปซูลที่ละลายได้ของ 1,1-ไดเมธิลเอธิล[(1s)-1{[2s,4r)-4-(7-คลอโร-4เมธอกซีไอโซควิโนลิน-1-อิลออกซี)-2-({1r,2s)-1-[(ไซโคลโพรพิลซัลโฟนิล) คาร์บาโมอิล]-2-เอธีนิลไซโคลโพรพิล}คาร์บาโมอิล)ไพร์โรลิดิน-1-อิล]คาร์บอนิล}-2,2-ไดเมธิลโพรพิล]คาร์บาเมต
IL235651B (en) A pharmaceutical preparation containing (1r, 4r) - 6&#39; - fluoro - n, n - dimethyl - 4 - phenyl - 4&#39;, 9&#39; - dihydro - 3&#39;h - spiro [cyclohexane - 1, 1&#39; - pyrano [3, 4 ,b] Indole] - 4 - amine and paracetamol or propacetamol
EP2890368A4 (en) RECIPE FOR A DOUBLE-LAYER COMPOSITE TABLET WITH ATORVASTATIN, IRBESARTAN AND MAGNESIUM CARBONATE
MX2013015272A (es) Cristales micronizados.
BR112014028564A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n , n-dimetil-4 ,9-di-hidro-3h-espiro[ciclo-hexano-1 ,1-pirano-[3,4,b]indol]-4-amina e um componente de ácido salicílico
BR112014028557A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n ,n-dimetil-4-fenil-4 ,9-di-hidro-3h-espiro[ciclohexano-1 ,1-pirano-[3,4,b]indol]-4- amina e um anticonvulsivo
AU2010903740A0 (en) Eye Mask for Under Eye Compression